Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) – Investment analysts at HC Wainwright reduced their Q3 2026 EPS estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.63) per share for the quarter, down from their previous forecast of ($0.57). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.39) EPS, Q1 2027 earnings at ($0.67) EPS, Q2 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.69) EPS, Q4 2027 earnings at ($0.71) EPS, FY2027 earnings at ($2.76) EPS, FY2028 earnings at ($2.13) EPS, FY2029 earnings at ($1.00) EPS and FY2030 earnings at ($0.18) EPS.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10).
Read Our Latest Report on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Stock Down 1.7%
NASDAQ ZNTL opened at $4.15 on Tuesday. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95. The business has a fifty day moving average of $4.32 and a 200-day moving average of $3.61. The stock has a market cap of $297.43 million, a price-to-earnings ratio of -2.13 and a beta of 1.92.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CTC Alternative Strategies Ltd. purchased a new stake in Zentalis Pharmaceuticals during the 1st quarter worth $29,000. Invesco Ltd. grew its stake in shares of Zentalis Pharmaceuticals by 8.6% in the fourth quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after buying an additional 14,961 shares in the last quarter. Barr E S & Co. raised its holdings in shares of Zentalis Pharmaceuticals by 43.8% during the 4th quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock valued at $78,000 after buying an additional 17,500 shares during the period. State of Wyoming acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $91,000. Finally, Vanguard Group Inc. boosted its holdings in Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock worth $4,386,000 after acquiring an additional 19,768 shares during the period.
Key Headlines Impacting Zentalis Pharmaceuticals
Here are the key news stories impacting Zentalis Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright reiterated its Buy rating and $10 price target, substantially above ZNTL’s recent trading level near $4.15. This indicates the firm continues to see meaningful potential upside, likely tied to the company’s oncology pipeline and future clinical or commercial progress.
- Neutral Sentiment: The analyst expects Zentalis to remain unprofitable for several years, with projected losses of $2.39 per share in fiscal 2026 and $2.76 per share in fiscal 2027. Estimates improve thereafter, but the company is still projected to post a $0.18-per-share loss in fiscal 2030.
- Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to a loss of $2.39 from $2.19 and lowered its fourth-quarter 2026 estimate to a loss of $0.66 from $0.60. It also cut its fiscal 2027 forecast to a loss of $2.76 from $2.32, suggesting higher expected cash burn or operating expenses.
- Negative Sentiment: Longer-term estimates were also reduced: fiscal 2028 EPS was lowered to a $2.13 loss from $1.80, fiscal 2029 to a $1.00 loss from $0.77, and fiscal 2030 to a $0.18 loss from $0.01. These revisions imply that profitability may arrive later than previously expected.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
Further Reading
- Five stocks we like better than Zentalis Pharmaceuticals
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
